Modality
mRNA
MOA
BCMA ADC
Target
CD19
Pathway
Sphingolipid
HNSCCCTCL
Development Pipeline
Preclinical
Feb 2024
→ Jul 2030
PreclinicalCurrent
NCT05816486
2,334 pts·HNSCC
2024-02→2030-07·Active
2,334 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-164.3y awayInterim· HNSCC
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Preclinical
Active
Catalysts
Interim
2030-07-16 · 4.3y away
HNSCC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05816486 | Preclinical | HNSCC | Active | 2334 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| Terazumab | Recursion | Phase 3 | AHR |